$1.03 Earnings Per Share Expected for Davita Inc (NYSE:DVA) This Quarter

Equities analysts predict that Davita Inc (NYSE:DVA) will post earnings of $1.03 per share for the current fiscal quarter, Zacks Investment Research reports. Six analysts have issued estimates for Davita’s earnings. The highest EPS estimate is $1.11 and the lowest is $0.96. Davita posted earnings per share of $1.05 in the same quarter last year, which would suggest a negative year-over-year growth rate of 1.9%. The company is expected to report its next quarterly earnings report on Wednesday, August 7th.

On average, analysts expect that Davita will report full-year earnings of $4.23 per share for the current year, with EPS estimates ranging from $4.17 to $4.34. For the next year, analysts anticipate that the firm will report earnings of $5.21 per share, with EPS estimates ranging from $4.73 to $5.52. Zacks’ EPS calculations are an average based on a survey of research firms that follow Davita.

Davita (NYSE:DVA) last announced its quarterly earnings results on Tuesday, May 7th. The company reported $0.91 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.95 by ($0.04). Davita had a return on equity of 13.96% and a net margin of 1.15%. The firm had revenue of $2.74 billion during the quarter, compared to analysts’ expectations of $2.82 billion. During the same period in the previous year, the company posted $1.05 earnings per share. The company’s quarterly revenue was down 3.7% compared to the same quarter last year.

A number of equities research analysts have recently issued reports on DVA shares. Deutsche Bank lowered their price target on shares of Davita from $68.00 to $66.00 and set a “buy” rating on the stock in a report on Thursday, May 9th. Zacks Investment Research raised shares of Davita from a “sell” rating to a “hold” rating in a report on Friday, May 10th. Finally, William Blair reissued a “buy” rating on shares of Davita in a report on Thursday, June 20th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and four have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $67.78.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. BlackRock Inc. raised its stake in Davita by 34.0% in the fourth quarter. BlackRock Inc. now owns 12,931,031 shares of the company’s stock valued at $665,428,000 after purchasing an additional 3,280,413 shares in the last quarter. Norges Bank purchased a new stake in Davita in the fourth quarter valued at approximately $274,676,000. Dimensional Fund Advisors LP raised its stake in Davita by 0.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,579,221 shares of the company’s stock valued at $132,708,000 after purchasing an additional 7,907 shares in the last quarter. Gates Capital Management Inc. raised its stake in Davita by 19.5% in the fourth quarter. Gates Capital Management Inc. now owns 2,226,221 shares of the company’s stock valued at $114,561,000 after purchasing an additional 362,588 shares in the last quarter. Finally, FMR LLC grew its position in Davita by 4.6% during the fourth quarter. FMR LLC now owns 2,032,270 shares of the company’s stock valued at $104,581,000 after acquiring an additional 88,540 shares during the last quarter. 87.65% of the stock is currently owned by institutional investors and hedge funds.

Shares of Davita stock traded up $0.87 on Monday, reaching $58.27. The stock had a trading volume of 1,103,038 shares, compared to its average volume of 1,701,854. Davita has a 1 year low of $43.40 and a 1 year high of $79.11. The stock has a market capitalization of $9.70 billion, a P/E ratio of 16.32, a P/E/G ratio of 0.62 and a beta of 1.59. The company has a current ratio of 1.12, a quick ratio of 1.11 and a debt-to-equity ratio of 2.06. The stock’s 50 day moving average price is $50.07.

Davita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

See Also: Analyst Ratings Trading

Get a free copy of the Zacks research report on Davita (DVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Davita (NYSE:DVA)

Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.